GE HealthCare (GEHC): SOFIE Deal Expands Radiopharmaceutical Network
Why it is trending
GE HealthCare agreed to acquire SOFIE Biosciences for $945 million in cash. The transaction would add 15 U.S. manufacturing sites and expand the production and distribution network for PET radiopharmaceuticals. It would also secure U.S. rights to the investigational FAPI-74 imaging agent, currently in Phase 3 development. The acquisition remains subject to regulatory approvals and other closing conditions.
Sector
Health care, medical technology and pharmaceutical diagnostics. GE HealthCare supplies imaging equipment, diagnostic agents, clinical software and related services.
Recent earnings
For Q2 2026, ended June 30, GE HealthCare reported revenue of $5.295 billion, up 5.7% year over year. GAAP diluted earnings were $1.24 per share, while adjusted earnings were $1.13. Tariff refunds and a lower tax rate benefited both earnings measures.
Pharmaceutical Diagnostics revenue increased 15.6% to $843 million. Management’s July outlook reaffirmed full-year adjusted earnings of $4.80–$5.00 per share and approximately $1.6 billion in free cash flow. Those figures remain forecasts.
ATA Auto Trend Indicator Review
GE HealthCare’s small black daily dots show SELL signals, while its larger green weekly dots show BUY signals. The timeframes are mixed, with the weekly BUY representing the dominant trend. The latest completed daily bar remains on SELL; the current weekly bar is still forming, and the last completed weekly signal was BUY. Earlier changes between green and black dots are historical.
Our proprietary ATA Auto Trend Indicator makes these signals easy to follow: small dots track daily buys and sells, while larger dots track weekly buys and sells. Green means buy; black means sell. The weekly timeframe represents the dominant trend. This clear visual approach helps you compare daily and weekly signals and support a more disciplined trading process.
WE PREPARE FOR THE NEXT MOVE RATHER THAN PREDICT IT.
Wednesday October 07, 2026